3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
5
Unspecified Adult Solid Tumor, Protocol Specific
1
Resectable Pancreatic Carcinoma
1
Resectable Pancreatic Cancer
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Advanced Pancreatic Cancer
1
Adenocarcinoma of the Pancreas
1
Adenocarcinoma
1
Interventions
Gemcitabine
27
Fluorouracil
25
Oxaliplatin
21
Cisplatin
19
Leucovorin
17
Bevacizumab
15
130-nm albumin-bound paclitaxel
13
Docetaxel
12
Capecitabine
12
Albumin-Bound Paclitaxel
12
Paclitaxel
11
Irinotecan
10
Carboplatin
9
pembrolizumab
7
Radiotherapy
6
Pemetrexed
6
Nivolumab
6
Erlotinib Hydrochloride
6
Cyclophosphamide
6
Trastuzumab
5
Ramucirumab
5
Ipilimumab
4
Everolimus
4
Crizotinib
4
Cetuximab
4
vandetanib
3
trastuzumab deruxtecan
3
sargramostim
3
folfirinox
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma
×
paricalcitol
×
Clear all
NCT03415854
2026-05-12
NABPLAGEMD
HonorHealth Research Institute
Phase 2
Completed
34 enrolled
11 charts